Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

Unmet Needs in Managing MDD Interpreting Thyroid Function Tests Using Thyroid Lab Tests Testing & Screening to Optimize Men's Health

Andy Studna

home / authors / andy-studna

Articles

Efsitora Alfa, Eli Lilly’s Once Weekly Insulin, Has Positive Topline Results in Two Trials /IMAGE CREDIT: © MichaelVi - stock.adobe.com

Efsitora Alfa, Eli Lilly’s Once Weekly Insulin, Has Positive Topline Results in Two Trials

Grace Halsey;Andy Studna

September 6th 2024

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

Teal Health Granted Breakthrough Device Designation for Self-Collect Cervical Cancer Screening Device / image credit cervical cancer concept ©ibreakstock/stock.adobe.com

Teal Health Granted Breakthrough Device Designation for Self-Collect Cervical Cancer Screening Device

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.